At 14.5% CAGR, the Europe Glycomic Therapeutics Market is projected to be worth US$ 88.66 billion by 2028, says Business Market Insights  

According to Business Market Insights’ research, the Europe glycomic therapeutics market was valued at US$ 37.00 billion in 2022 and is expected to reach US$ 88.66 billion by 2028, registering an annual growth rate of 14.5% from 2022 to 2028. Wide application in various disorders followed by the development of new treatment processes and increasing research and development in the field of glycomic therapeutics are the critical factors attributed to the market expansion.                  

Glycans may be exceedingly complex and are found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. For instance, In March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients suffering from advanced cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans.In April 2022, CPTAC glycoproteomic researchers developed "Peptide-First" multi-attribute glycan identification method. According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animals through glycomics studies. Such advancements in the field of glycomics propel the glycomics therapeutics market growth significantly.

On the contrary, high cost of equipment hampers market Europe glycomic therapeutics market. 

• Based on class, the market is segmented into isolated and synthetic. The synthetic segment held 56.11% market share in 2022, amassing US$ 20.76 billion. It is projected to garner US$ 49.03 billion by 2028 to expand at 15.4% CAGR during 2022–2028.    
• Based on structure, the market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held 45.24% market share in 2022, amassing US$ 16.74 billion. It is projected to garner US$ 39.86 billion by 2028 to expand at 15.6% CAGR during 2022–2028.
• Based on indications, the market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, Gaucher’s disease, mps-1 & iv,cancer, alzheimer’s disease, influenza type a & b, and others. The influenza type a & b segment held 36.75% market share in 2022, amassing US$ 13.60 billion. It is projected to garner US$ 32.75 billion by 2028 to expand at 15.8% CAGR during 2022–2028.
• Based on mode of action, the market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held 38.62% market share in 2022, amassing US$ 14.29 billion. It is projected to garner US$ 33.93 billion by 2028 to expand at 15.5% CAGR during 2022–2028.
• Based on country, the Europe glycomic therapeutics market has been categorized into U.K., Germany, France, Italy, Spain and Rest of Europe. Our regional analysis states that Germany captured 29.45% market share in 2022. It was assessed at US$ 10.90 billion in 2022 and is likely to hit US$ 25.52 billion by 2028, exhibiting a CAGR of 15.2% during the forecast period.    

Key players dominating the Europe glycomic therapeutics market are IntellihepLtd;BioMarinPharmaceuticalInc.;GenzymeCorporation(Sanofi);BayerAG;Alzheon,Inc.;GlycoMar;GlaxoSmithKline plc.;F. Hoffmann-La Roche Ltd.

•  In May,2022; Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products.

• In May,2021; Alzheon, Inc. announced that it has entered into a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) to develop the first clinical assay to measure neurotoxic beta-amyloid (amyloid, A?) oligomers in human cerebrospinal fluid (CSF). Under the collaboration agreement, IOCB applied Alzheon’s technology for detecting oligomers into a customized clinical assay in human CSF, to be developed by the IOCB and commercialized by Alzheon.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com